<p>This episode examines CAR T-cell therapy’s early successes, broader promise, and emerging risks, as the FDA considers reports of occasional secondary cancers.</p>
<p>A full transcript of this episode is available at nejm.org/doi/full/10.1056/NEJMp2400701.</p>

This episode examines CAR T-cell therapy’s early successes, broader promise, and emerging risks, as the FDA considers reports of occasional secondary cancers. A full transcript of this episode is available at nejm.org/doi/full/10.1056/NEJMp2400701.

CAR T-Cells and Safety Signals

From the New England Journal of Medicine, welcome to “Intention to Treat,” a podcast exploring the most complicated, perplexing, and fascinating issues facing medicine today. From groundbreaking research, to clinical advances, to personal stories from doctors and their patients, we give you a behind-the-scenes look at discoveries that are changing medical practice and provide you with the knowledge to thrive on the front lines of health care.

Share CAR T-Cells and Safety Signals

Sign up to save your podcasts

CAR T-Cells and Safety Signals

CAR T-Cells and Safety Signals

More shows like Intention to Treat

Fresh Air

Wait Wait... Don't Tell Me!

Global News Podcast

NEJM This Week

NEJM Interviews

JAMA Clinical Reviews

TED Health

Clinical Conversations

The Curbsiders Internal Medicine Podcast

Core IM | Internal Medicine Podcast

Curbside Consults

Leadership Conversations

Annals On Call Podcast

Harrison's PodClass: Internal Medicine Cases and Board Prep

The Journal.

The Curious Clinicians

NEJM AI Grand Rounds

Not Otherwise Specified